COVID-19

20 trials 6 recruiting MedDRA PT
20 Registered trials
6 Recruiting
14 Unique sponsors
26 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 13
J Anti-infectives (ATC J) 4
C Cardiology (ATC C) 1
H Endocrinology (ATC H) 1
L Oncology (ATC L) 1
R Respiratory (ATC R) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 18 substances
Antiviral 4 substances
HIV protease inhibitor 1 substance
ARB 1 substance
Corticosteroid 1 substance
Receptor fusion protein 1 substance
Phase III: 7 Phase II/III: 2 Phase II: 3 Phase IV: 2 Phase I: 2 Phase I (Other): 3 Phase I (First in Human): 1

Filter these 20 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 20 trials

Phase III

7 trials
  • Atea Pharmaceuticals Inc. Commercial
    BEMNIFOSBUVIR HEMISULFATE; NIRMATRELVIR
    2023-504540-33-00 6 countries 2023 n=354
    Ended
  • BIOTEST AG Commercial
    TRIMODULIN (HUMAN IGM, IGA, IGG SOLUTION)
    2024-513002-60-00 9 countries 2022 n=198
    Ended
  • Merck Sharp & Dohme LLC Commercial
    MOLNUPIRAVIR
    2023-507227-36-00 8 countries 2025 n=767
    Recruiting
  • Goethe University Frankfurt Academic
    LOSARTAN POTASSIUM; PREDNISOLONE
    2024-516463-84-00 2 countries 2022 n=280
    Ended
  • University Of Minnesota Academic
    (6E)-6-[(6-CHLORO-2-METHYL-2H-INDAZOL-5-YL)IMINO]-3-[(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)METHYL]-1-[(2,4,5-TRIFLUOROPHENYL)METHYL]-1,3,5-TRIAZINANE-2,4-DIONE
    2022-501020-19-01 6 countries 2023 n=295
    Ended
  • University Of Minnesota Academic
    ABATACEPT
    2023-504487-41-00 9 countries 2023 n=345
    Ended
  • University Of Minnesota Academic
    ANTI-SARS-COV-2 POLYCLONAL HYPERIMMUNE GLOBULIN
    2023-508105-24-00 3 countries 2021 n=160
    Recruiting

Phase II/III

2 trials
  • Gilead Sciences Inc. Commercial
    GS-5245
    2023-503282-27-00 5 countries n=22
    Ended
  • Pfizer Inc. Commercial
    NIRMATRELVIR; RITONAVIR; RITONAVIR, NIRMATRELVIR
    2023-509773-23-00 2 countries 2023 n=39
    Recruiting

Phase II

3 trials
  • Azienda Ospedaliero Universitaria Di Modena Academic
    IMP not specified
    2023-504641-32-00 1 country n=60
    Not authorised
  • Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C Academic
    REMDESIVIR
    2024-519272-96-00 1 country 2025 n=15
    Recruiting
  • Kinarus AG Academic
    PAMAPIMOD; PIOGLITAZONE HYDROCHLORIDE
    2022-500244-37-00 1 country 2022 n=150
    Ended

Phase IV

2 trials
  • Finnish Institute For Health And Welfare Academic
    5'-CAPPED MRNA ENCODING SARS-COV-2, VARIANT LP.8.1, SPIKE PROTEIN, PRE-FUSION STABILISED (K981P AND V982P); BRETOVAMERAN; ELASOMERAN; ELASOMERAN, IMELASOMERAN; RAXTOZINAMERAN; SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER; SARS-COV-2, SPIKE PROTEIN, RECOMBINANT, EXPRESSED IN SF9 CELLS DERIVED FROM SPODOPTERA FRUGIPERDA; TOZINAMERAN; TOZINAMERAN, FAMTOZINAMERAN
    2024-517357-27-00 1 country 2021 n=4,000
    Ended
  • Universiteit Maastricht Academic
    MONTELUKAST
    2022-501559-99-00 1 country 2023 n=682
    Ended

Phase I

2 trials
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2025-521395-63-00 1 country 2025 n=28
    Ended
  • Inserm Academic
    IMP not specified
    2023-504594-20-00 1 country 2025 n=215
    Ended

Phase I (Other)

3 trials
  • NextCell Pharma AB Commercial
    IMP not specified
    2024-519391-11-00 1 country n=9
    Pending
  • Pfizer Inc. Commercial
    IMP not specified
    2024-517797-14-00 1 country 2024 n=20
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2025-525041-43-00 1 country 2026 n=18
    Recruiting

Phase I (First in Human)

1 trial
  • Inserm Academic
    BRETOVAMERAN; LVT-001
    2024-510589-17-00 1 country 2025 n=238
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Pfizer Inc. Commercial 3 Phase II/III, Phase I (Other) 2
University Of Minnesota Academic 3 Phase III 1
Merck Sharp & Dohme LLC Commercial 2 Phase I, Phase III 1
Inserm Academic 2 Phase I, Phase I (First in Human) 1
Gilead Sciences Inc. Commercial 1 Phase II/III 0
NextCell Pharma AB Commercial 1 Phase I (Other) 0
Atea Pharmaceuticals Inc. Commercial 1 Phase III 0
BIOTEST AG Commercial 1 Phase III 0
Azienda Ospedaliero Universitaria Di Modena Academic 1 Phase II 0
Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C Academic 1 Phase II 1
Kinarus AG Academic 1 Phase II 0
Goethe University Frankfurt Academic 1 Phase III 0
Finnish Institute For Health And Welfare Academic 1 Phase IV 0
Universiteit Maastricht Academic 1 Phase IV 0
New trials by year
2021
2
2022
3
2023
5
2024
1
2025
5
2026
1
← All indication landscapes